BioNTech SE (LON:0A3M)

Market Cap	16.53B -23.2%
Revenue (ttm)	2.50B +4.3%
Net Income	-991.10M
EPS	-4.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,904
Average Volume	19,505
Open	90.75
Previous Close	88.95
Day's Range	87.71 - 91.80
52-Week Range	79.51 - 125.70
Beta	1.53
RSI	36.26
Earnings Date	Mar 10, 2026

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 7,807
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3M

Financial Performance

In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.

Financial numbers in EUR